CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Simtuzumabbiological
Likely dose
Simtuzumab 700 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01707472
NCT01707472Phase 2Completed
CompareCT.gov

A Phase 2a Study of an Anti-LOXL2 Monoclonal Antibody (GS-6624) in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis

Gilead Sciences·interventional·Posted Oct 16, 2012·Updated Nov 5, 2019

In Brief

A Phase 2 clinical trial evaluating Simtuzumab for Liver Fibrosis and 3 related conditions. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 16, 2012
Enrollment StartOct 4, 2012
Primary CompletionOct 17, 2014
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 13.7 years ago

Interventions

Simtuzumabbiological

700 mg intravenously for a total of 12 infusions.